Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial

Based on the S-TRAC results, sunitinib is approved as adjuvant treatment for adult patients at high risk of recurrent RCC following nephrectomy. Here, the authors report the results of an integrated multi-omics tumor analysis of 171 patients from the trial and identify specific molecular subtypes as...

Descripció completa

Dades bibliogràfiques

Autors principals:	Robert J. Motzer, Jean-François Martini, Xinmeng J. Mu, Michael Staehler, Daniel J. George, Olga Valota, Xun Lin, Hardev S. Pandha, Keith A. Ching, Alain Ravaud
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2022-10-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-022-33555-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!